Early diagnostic indices for the prevention of Alzheimer's disease

Annals of Medicine

Volumn 30, Issue 6, 1998, Pages 553-559

  Soininen, Hilkka S ^a   Scheltens, Philip ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Apolipoprotein E; Dementia; Diagnostics; Genetics; Hippocampus; Magnetic resonance imaging; Memory

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FOLLOW UP; GENETIC SUSCEPTIBILITY; HEREDITY; HIPPOCAMPUS; HUMAN; IMAGING; MOLECULAR GENETICS; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM;

EID: 0032408854     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809002604     Document Type: Article

References (58)

1. Albert MS. Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci U S A 1996; 93: 13547-51.
2. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
3. Hänninen T, Hallikainen M, Koivisto K, et al. A follow-up study of age-associated memory impairment: neuro-psychological predictors of dementia. J Am Geriatr Soc 1995; 43: 1007-15.
4. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. APOE and Alzheimer disease Meta Analysis Consortium. JAMA 1997; 278: 1349-56.
5. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 1: 575-80.
6. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 1993; 90: 9649-53.
7. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995; 69: 757-61.
8. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of patients carrying apolipoprotein E ε4 allele. Neurosci Lett 1995; 187: 79-82.
9. Poirier J. Apolipoprotein E in animal models of CNS injury and Alzheimer's disease. Trends Neurosci 1994; 17: 525-30.
10. Arendt T, Schindler C, Bruckner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein ε4 allele. J Neurosci 1997; 17: 516-29.
11. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995; 333: 1242-7.
12. Helkala EL, Koivisto K, Hänninen T, et al. The association of apolipoprotein E with memory: a population based study. Neurosci Lett 1995; 191: 141-4.
13. Helkala EL, Koivisto K, Hänninen T, et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett 1996; 204: 177-80.
14. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with APOE-ε4 allele in nondemented older adults. Neurology 1995; 45: 2203-6.
15. Small GW, Komo S, LaRue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996; 802: 70-8.
16. Petersen RD, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-8.
17. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996; 46: 149-54.
18. Bhatia S, Bookheimer SY, Gaillard WD, Theodore WH. Measurement of whole temporal lobe and hippocampus for MR volumetry. Normative data. Neurology 1993; 43: 2006-10.
19. Press GA, Amaral DG, Squire LR. Hippocampal abnormalities in amnesic patients revealed by high-resolution magnetic resonance imaging. Nature 1989; 341: 54-7.
20. Seab JP, Jagust WJ, Wong STS, Roos MS, Reed BR, Budinger TP. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 1988; 8: 200-8.
21. Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 1991; 41: 51-4.
22. Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993; 50: 949-54.
23. Pantel J, Schröder J, Schad LR. Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Psychol Med 1997; 27: 221-9.
24. Ikeda M, Tanabe H, Nakagawa Y, et al. MRI based quantitative assessment of the hippocampal region in very mild to moderate Alzheimer's disease. Neuroradiology 1994; 36: 7-10.
25. Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183-8.
26. Pearlson GD, Harris G, Powers RE. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry 1992; 49: 402-8.
27. Laakso MP, Soininen H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. J Neural Transm Park Dis Dement Sect 1995; 9: 73-86.
28. Laakso MP, Partanen K, Riekkinen P Jr, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: a MRI study. Neurology 1996; 46: 678-81.
29. Cuenod CA, Denys A, Michot JL, et al. Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. Arch Neurol 1993; 50: 941-5.
30. Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996; 119: 2001-7.
31. Julin P, Almkvist O, Basun H, et al. Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer amyloid protein mutation. Alzheimer Dis Assoc Disord 1998; 12: 49-53.
32. Scheltens P, Leys D, Barkhof F, et al. Atrophy of the medial temporal lobes on MRI in Alzheimer's disease and normal aging. Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-72.
33. Erkinjuntti T, Lee DH, Gao F, et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. Arch Neurol 1993; 50: 305-10.
34. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of MRI and SPECT in the diagnosis of dementia in an open population of very old individuals. Alzheimer Dis Assoc Disord 1997: 11: 63-70.
35. Laakso M, Soininen H, Partanen K et al. Hippocampal volumetry in Alzheimer's disease, sensitivity and specificity of the, analysis of incorrectly classified subjects. Neurobiol Aging 1998; 19: 23-31.
36. Altshuler LL, Casanova MF, Goldberg TE, Kleinman JE. The hippocampus and parahippocampus in schizophrenic, suicide and control brains. Arch Gen Psychiatry 1990; 47: 1029-34.
37. Bigler E, Blatter DD, Anderson CV. Hippocampal volume in normal aging and traumatic brain injury. Am J Neuroradiol 1997; 18: 11-23.
38. Golomb J, DeLeon MJ, Kluger A, George AE, Tarshish C, Ferris SH. Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch Neurol 1993; 50: 967-73.
39. De Leon MJ, George AE, Golomb J, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging 1997; 18: 1-11.
40. Launer LJ, Scheltens P, Lindeboom J, Barkhof F, Weinstein HC, Jonker C. Medial temporal lobe atrophy in an open population of very old persons: cognitive, brain atrophy, and sociomedical correlates. Neurology 1995; 45: 747-52.
41. Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 1996; 348: 94-7.
42. Rombouts SARB, Barkhof F, Hoogenraad FGC, Sprenger M, Valk J, Scheltens P. Test-retest analysis of the activated area in the human visual cortex using functional MR imaging. Am J Neuroradiol 1997; 18: 1317-22.
43. Rombouts SARB, Barkhof F, Sprenger M, Scheltens P. The functional basis of ocular dominance: functional MRI (fMRI) findings. Neurosci Lett 1996; 221: 1-4.
44. Rombouts SARB, Machielsen WCM, Witter MP, Barkhof F, Lindeboom J, Scheltens P. Visual association encoding activates the medial temporal lobe: a functional magnetic resonance imaging study. Hippocampus 1997; 7: 594-601.
45. Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-500.
46. Soininen HS, Riekkinen PJ Sr. Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci 1996; 19: 224-8.
47. Lehtovirta M, Laakso MP, Soininen H, et al. Volumes of hippocampus, amygdala, and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995; 67: 65-72.
48. Soininen H, Partanen K, Pitkänen A, et al. Decreased hippocampal volume asymmetry on MRI scans in nondemented elderly subjects carrying apolipoprotein E ε4 allele. Neurology 1995; 45: 391-2.
49. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-70.
50. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-8.
51. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995; 38: 649-52.
52. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease. Mol Chem Neuropathol 1995; 26: 231-45.
53. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 186: 189-91.
54. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluid: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995; 186: 181-3.
55. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995; 37: 512-8.
56. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-34.
57. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995; 45: 788-93.
58. Tapiola T, Lehtovirta M, Ramberg J, et al. CSF tau is related to APOE genotype in early Alzheimer's disease. Neurology 1998; 50: 169-74.